Search Results - "da Silva Lima, Gabriel Paiva"

Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study by Ferrari, Michel Dominique, Reuter, Uwe, Goadsby, Peter J, Paiva da Silva Lima, Gabriel, Mondal, Subhayan, Wen, Shihua, Tenenbaum, Nadia, Pandhi, Shaloo, Lanteri-Minet, Michel, Stites, Tracy

“…ObjectiveTo evaluate individual and group long-term efficacy and safety of erenumab in individuals with episodic migraine (EM) for whom 2–4 prior preventatives…”
Get full text

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study by Hershey, Andrew D., Paiva da Silva Lima, Gabriel, Pannacciulli, Nicola, Mackowski, Mia, Koukakis, Reija, McVige, Jennifer Williams

“…Erenumab, a fully human monoclonal antibody targeting the calcitonin gene‐related peptide receptor, is efficacious and safe for prevention of attacks of…”
Get full text

Timing and durability of response to erenumab in patients with episodic migraine by McAllister, Peter J., Turner, Ira, Reuter, Uwe, Wang, Andrea, Scanlon, James, Klatt, Jan, Chou, Denise E., Paiva da Silva Lima, Gabriel

“…Objective We sought to evaluate temporal response patterns to erenumab treatment in patients with episodic migraine. Background Although many patients treated…”
Get full text

Timing and durability of response to erenumab in patients with chronic migraine by Tepper, Stewart J., Lucas, Sylvia, Ashina, Messoud, Schwedt, Todd J., Ailani, Jessica, Scanlon, James, Klatt, Jan, Chou, Denise E., Wang, Andrea, Paiva da Silva Lima, Gabriel

“…Background Erenumab is a human anti‐calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess…”
Get full text

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial by Hirata, Koichi, Takeshima, Takao, Sakai, Fumihiko, Numachi, Yotaro, Yoshida, Ryuji, Koukakis, Reija, Hasebe, Miki, Yui, Daishi, da Silva Lima, Gabriel Paiva, Cheng, Sunfa

“…ObjectivesTo evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III…”
Get full text

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis by Kitamura, Shigekazu, Takeshima, Takao, Yui, Daishi, da Silva Lima, Gabriel Paiva, Koukakis, Reija, Peng, Cheng, Yoshida, Ryuji, Numachi, Yotaro, Hasebe, Miki

“…Introduction Erenumab, a fully human monoclonal antibody against the calcitonin gene-related peptide receptor, is approved in Japan for the prevention of adult…”
Get full text

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial by Ashina, Messoud, Goadsby, Peter J., Reuter, Uwe, Silberstein, Stephen, Dodick, David W., Xue, Fei, Zhang, Feng, Paiva da Silva Lima, Gabriel, Cheng, Sunfa, Mikol, Daniel D.

“…Background and purpose Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life in studies lasting 3 to…”
Get full text

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials by Ashina, Messoud, Goadsby, Peter J, Dodick, David W, Tepper, Stewart J, Xue, Fei, Zhang, Feng, Brennan, Francis, Paiva da Silva Lima, Gabriel

“…Migraine with aura may respond differently to therapies than migraine without aura. Individuals with migraine with aura have an elevated vascular risk,…”
Get more information

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study by Diener, Hans-Christoph, Ashina, Messoud, Ritter, Shannon, Paiva Da Silva Lima, Gabriel, Rasmussen, Soeren, Zielman, Ronald, Tfelt-Hansen, Peer

“…This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients…”
Get more information

Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies by Hirata, Koichi, Takeshima, Takao, Sakai, Fumihiko, Imai, Noboru, Matsumori, Yasuhiko, Tatsuoka, Yoshihisa, Numachi, Yotaro, Yoshida, Ryuji, Peng, Cheng, Mikol, Daniel D., Lima, Gabriel Paiva da Silva, Cheng, Sunfa

“…Purpose In two 24‐week migraine prevention studies in Japan, erenumab was associated with significantly greater reductions in migraine frequency versus placebo…”
Get full text

Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study by Goadsby, Peter J., Reuter, Uwe, Lanteri-Minet, Michel, Paiva da Silva Lima, Gabriel, Hours-Zesiger, Peggy, Fernandes, Chrystel, Wen, Shihua, Tenenbaum, Nadia, Kataria, Aditi, Ferrari, Michel D., Klatt, Jan

“…To report the efficacy and safety of erenumab among patients with episodic migraine (EM) who were unsuccessful on 2 to 4 preventive treatments observed at week…”
Get full text

Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study by Reuter, Uwe, Goadsby, Peter J, Ferrari, Michel D, Da Silva Lima, Gabriel Paiva, Mondal, Subhayan, Kalim, Jawed, Hasan, Fatima, Wen, Shihua, Arkuszewski, Michal, Pandhi, Shaloo, Stites, Tracy, Lanteri-Minet, Michel

“…The LIBERTY study assessed the efficacy and safety of erenumab in participants with episodic migraine (EM) and 2-4 prior preventive treatment failures. The…”
Get full text

Long-term Safety and Tolerability of Erenumab In Episodic Migraine: A Pooled Analysis From Two Clinical Trials and Their Extension Phases (P3-2.005) by Ashina, Messoud, Reuter, Uwe, Dodick, David, Zhang, Feng, Ritter, Shannon, Stites, Tracy, da Silva Lima, Gabriel Paiva, Arkuszewski, Michal, Goadsby, Peter

“…Abstract only…”
Get full text

Three-Year Efficacy and Safety of Erenumab in Participants with Episodic Migraine and 2–4 Prior Preventive Treatment Failures: Results from the LIBERTY Study (P1-1.Virtual) by Reuter, Uwe, Goadsby, Peter, Ferrari, Michel, da Silva Lima, Gabriel Paiva, Mondal, Subhayan, Wen, Shihua, Stites, Tracy, Arkuszewski, Michal, Lanteri-Minet, Michel, Pandhi, Shaloo

“…Abstract only…”
Get full text

Benefit of Migraine Prevention with Erenumab in Patients Receiving Background Standard-of-care Acute Treatment (1381) by Starling, Amaal, Tepper, Stewart, Bernstein, Carolyn, Ailani, Jessica, Zhang, Feng, da Silva Lima, Gabriel Paiva, Chou, Denise

“…Abstract only…”
Get full text

Cardiovascular Safety of Erenumab in Patients with Migraine and Aura (1209) by Ashina, Messoud, Goadsby, Peter, Dodick, David, Tepper, Stewart, Xue, Fei, Zhang, Feng, Olearczyk, Jeffrey, da Silva Lima, Gabriel Paiva

“…Abstract only…”
Get full text

Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study (2328) by Ashina, Messoud, Goadsby, Peter, Reuter, Uwe, Silberstein, Stephen, Dodick, David, Zhang, Feng, Xue, Fei, Cheng, Sunfa, Chou, Denise, da Silva Lima, Gabriel Paiva

“…Abstract only…”
Get full text

Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies by Lipton, Richard B, Dodick, David W, Kudrow, David, Reuter, Uwe, Tenenbaum, Nadia, Zhang, Feng, Lima, Gabriel Paiva da Silva, Chou, Denise E, Mikol, Daniel D

“…Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the…”
Get more information

Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study by Goadsby, Peter J., Reuter, Uwe, Lanteri-Minet, Michel, Paiva da Silva Lima, Gabriel, Hours-Zesiger, Peggy, Fernandes, Chrystel, Wen, Shihua, Tenenbaum, Nadia, Kataria, Aditi, Ferrari, Michel D., Klatt, Jan

Get full text

Effect of Erenumab on Patient - Reported Outcomes in Patients With Episodic Migraine From Asia, the Middle East and Latin America: The EMPOwER Study (P16-2.006) by Wang, Shuu-Jiun, Roxas, Artemio A., Saravia, Bibiana, Kim, Byung-kun, Chowdhury, Debashish, Riachi, Naji, Tai, Mei-Ling Sharon, Tanprawate, Surat, Tran, Tai Ngoc, Zhao, Yi Jing, da Silva Lima, Gabriel Paiva, Pandhi, Shaloo, Wen, Shihua, Mondal, Subhayan, Ecochard, Laurent, Arkuszewski, Michal

“…Abstract only…”
Get full text